• April 7- Specialty pharmaceuticals company Mallinckrodt Plc agreed to buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel.

  • Roche to buy molecular diagnostics company IQuum Monday, 7 Apr 2014 | 3:31 AM ET

    GENEVA— Swiss drug maker Roche plans to buy IQuum, Inc., a U.S. company that specializes in molecular diagnostics and sample testing, in a deal worth up to $450 million. Roche said Monday that it will pay $275 million upfront for the privately held IQuum, based in Marlborough, Massachusetts.

  • India's Sun Pharma to buy Ranbaxy in $4 bln deal Monday, 7 Apr 2014 | 2:26 AM ET

    MUMBAI, India— India's Sun Pharmaceutical Industries is buying troubled generic drugmaker Ranbaxy Laboratories in a $4 billion deal, the companies said Monday. Shares of Ranbaxy, which is 63- percent owned by Japan's Daiichi Sankyo, were down 4.8 percent on the Bombay Stock Exchange.

  • *Ranbaxy shareholders to get 0.8 Sun Pharma share for each Ranbaxy share. Ranbaxy, India's No.1 drugmaker by sales and 63.4 percent held by Daiichi Sankyo Co Ltd, is banned from exporting drug ingredients to the United States, while Sun Pharmaceutical's Karkhadi plant is also barred from shipping products by the U.S. Food and Drug Administration.

  • Drugmaker GSK investigates alleged bribery in Iraq Sunday, 6 Apr 2014 | 7:21 PM ET

    *GSK says investigating alleged "improper conduct" in Iraq. *Iraq issue follows claims of extensive corruption in China. LONDON, April 6- Drugmaker GlaxoSmithKine, already facing corruption accusations in China, is now investigating allegations of bribery in Iraq, the British company said on Sunday.

  • MUMBAI, April 7- An Indian drugs regulator is among the first to admit that oversight of the nation's huge pharmaceutical industry can be patchy. G.L. Singhal, chief regulator of northern Haryana state, a drugs manufacturing hub, says he needs double the number of inspectors if he is to properly scrutinise factories there.

  • April 4- Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent.

  • *Deal could have created a $24 billion generic drugs group. STOCKHOLM, April 4- Sweden's Meda AB said on Friday it had rejected a takeover approach by U.S. generic drugmaker Mylan Inc, scuppering a potential deal to create a combined company worth around $24 billion.

  • *Deal could create a $23 billion drug company. STOCKHOLM, April 4- Shares in drug maker Meda AB were halted on Friday following a media report that Mylan Inc is looking to acquire its smaller Swedish rival in a move that would create a $23 billion company.

  • *Deal could create a $23 billion drug company. *Meda confirms has had initial talks with Mylan- report. STOCKHOLM, April 4- Generic drug maker Mylan Inc is looking to buy Swedish rival Meda AB in a deal that would create a $23 billion pharmaceutical company, the Financial Times reported.

  • April 3- Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.

  • ZURICH, April 3- Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday. In a hearing that took place on March 28, the Delhi court ordered that Biocon cannot manufacture, sell or export vildagliptin until the next court hearing, Novartis said in an emailed statement.

  • MannKind shares soar as diabetes drug gets nod Wednesday, 2 Apr 2014 | 8:10 AM ET
    MannKind's David Thomson

    U.S. health advisers recommended approval of MannKind's inhaled diabetes drug, and said the treatment could help those wary of needles.

  • April 1- The U.S. Food and Drug Administration found that a drug ingredient manufactured at a GlaxoSmithKline Plc plant in Ireland was contaminated and said the company did not take sufficient action to resolve the problems.

  • FDA said GSK did not fully investigate a list of objectional conditions the regulator sent after its inspection of the manufacturing plant at Cork, Ireland in October. The FDA said its investigator found that a certain drug ingredient, the name of which was not disclosed, was contaminated with material from the plant's pharmaceutical waste tank.

  • April 1- The U.S. Food and Drug Administration found contamination of drug ingredients manufactured at a GlaxoSmithKline Plc plant in Ireland and said the company did not take sufficient action to resolve the problems.

  • FTI Consulting managing director Barbara Ryan provides insight on new drugs showing dramatic improvement in the standard of care for high cholesterol.

  • New class of cholesterol drugs     Monday, 31 Mar 2014 | 1:19 PM ET

    CNBC's Dominic Chu reports on news out about a special new drug that could combat cholesterol.

  • *Up to 100 mln pounds for new drug manufacturing in Africa. *GSK looks at Rwanda, Ghana and Ethiopia for new factories. France's Sanofi has also highlighted Africa as a promising market.

  • WASHINGTON, March 31- The U.S. Supreme Court on Monday agreed to hear an appeal filed by Teva Pharmaceutical Industries Ltd in a patent fight over top-selling multiple sclerosis drug Copaxone, a move that could deter generic manufacturers from introducing cheaper versions onto the market as soon as May.

Most Popular Video

Thursday, 17 Apr 2014 | 11:00 AM ET

Phil LeBeau has the details on the latest rides at this year's New York Auto Show.

Monday, 14 Apr 2014 | 11:43 AM ET

Dr. Steven Horng, Beth Israel Deaconess Medical Center, explains how Google Glass provided crucial support in an emergency situation and helped save a life.

Tuesday, 15 Apr 2014 | 11:36 PM ET

John Sculley, former Apple CEO and Managing Partner at Inflexionpoint, expects Alibaba to push on with its buying spree after listing in the U.S.